{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:16:57Z","timestamp":1791418617744,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41440-023-01324-9","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T10:02:24Z","timestamp":1685527344000},"page":"1892-1899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?"],"prefix":"10.1038","volume":"46","author":[{"given":"Kosuke","family":"Sawami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80:2361\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/hr.2017.67","volume":"40","author":"Y Tatsumi","year":"2017","unstructured":"Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res. 2017;40:795\u2013806.","journal-title":"Hypertens Res"},{"key":"1324_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400:1803\u201320.","journal-title":"Lancet."},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","volume":"148","author":"VT Samuel","year":"2012","unstructured":"Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852\u201371.","journal-title":"Cell."},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","volume":"380","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601\u201310.","journal-title":"Lancet."},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","volume":"321","author":"AI Adler","year":"2000","unstructured":"Adler AI. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412\u20139.","journal-title":"BMJ."},{"key":"1324_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group.","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703\u201313.","journal-title":"BMJ."},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","volume":"79","author":"MD Kelsey","year":"2022","unstructured":"Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. J Am Coll Cardiol. 2022;79:1849\u201357.","journal-title":"J Am Coll Cardiol"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:e177\u2013e232.","journal-title":"J Am Coll Cardiol"},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S158\u2013S190.","journal-title":"Diabetes Care"},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323. 2019","journal-title":"Eur Heart J"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, ADVANCE Collaborative Group, MacMahon S, ADVANCE Collaborative G, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829\u201340.","journal-title":"Lancet."},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahl\u00f6f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755\u201362.","journal-title":"Lancet."},{"key":"1324_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603\u201315.","journal-title":"JAMA."},{"key":"1324_CR17","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1324_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/HJH.0000000000003056","volume":"40","author":"R Kreutz","year":"2022","unstructured":"Kreutz R, Brunstr\u00f6m M, Thomopoulos C, Carlberg B, Mancia G. Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review. J Hypertens. 2022;40:839\u201346.","journal-title":"J Hypertens"},{"key":"1324_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","volume":"5","author":"K Ueki","year":"2017","unstructured":"Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomized controlled trial. Lancet Diabetes Endocrinol. 2017;5:951\u201364.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1324_CR20","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1210\/jc.2011-0622","volume":"96","author":"H Sone","year":"2011","unstructured":"Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: sub analysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96:3448\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"1324_CR21","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","volume":"141","author":"SV Arnold","year":"2020","unstructured":"Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020;141:e779\u2013e806.","journal-title":"Circulation."},{"key":"1324_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol. 2022;10:645\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1324_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0140-6736(93)93004-K","volume":"341","author":"LA Stewart","year":"1993","unstructured":"Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341:418\u201322.","journal-title":"Lancet."},{"key":"1324_CR24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-8587(22)00311-4","volume":"10","author":"W Li","year":"2022","unstructured":"Li W, Jingjing Z, Yuan Y. Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes. Lancet Diabetes Endocrinol. 2022;10:840\u20131.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1324_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S2213-8587(22)00191-7","volume":"10","author":"LM Ruilope","year":"2022","unstructured":"Ruilope LM, Ruiz-Hurtado G. Blood pressure control according to type 2 diabetes status. Lancet Diabetes Endocrinol. 2022;10:612\u20133.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1324_CR26","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia."},{"key":"1324_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41440-021-00665-7","volume":"44","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Node K. Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. Hypertens Res. 2021;44:897\u2013905.","journal-title":"Hypertens Res"},{"key":"1324_CR28","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386:2024\u201334.","journal-title":"N Engl J Med"},{"key":"1324_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40256-020-00423-z","volume":"21","author":"CI Liakos","year":"2021","unstructured":"Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs. 2021;21:123\u201337.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1324_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20313-5","volume":"12","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Sato K, et al. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Sci Rep. 2022;12:16106.","journal-title":"Sci Rep"},{"key":"1324_CR31","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","volume":"139","author":"K Kario","year":"2018","unstructured":"Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the Randomized, Placebo-Controlled SACRA Study. Circulation. 2018;139:2089\u201397.","journal-title":"Circulation."},{"key":"1324_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-022-01492-x","volume":"21","author":"CC van Ruiten","year":"2022","unstructured":"van Ruiten CC, Smits MM, Kok MD, Sern\u00e9 EH, van Raalte DH, Kramer M, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21:63.","journal-title":"Cardiovasc Diabetol"},{"key":"1324_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12933-022-01611-8","volume":"21","author":"K Sawami","year":"2022","unstructured":"Sawami K, Tanaka A, Node K. Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2022;21:176.","journal-title":"Cardiovasc Diabetol"},{"key":"1324_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15\u201330.","journal-title":"Cell Metab"},{"key":"1324_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.120.14868","volume":"76","author":"FL Martins","year":"2020","unstructured":"Martins FL, Bailey MA, Girardi ACC. Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na+\/H+ exchanger isoform 3, renal angiotensin II, and insulin sensitivity. Hypertension. 2020;76:839\u201348.","journal-title":"Hypertension."},{"key":"1324_CR36","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"1324_CR37","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"1324_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"1324_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152\u201361.","journal-title":"Eur Heart J"},{"key":"1324_CR40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"1324_CR41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","volume":"44","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021;44:1239\u201350.","journal-title":"Hypertens Res"},{"key":"1324_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12933-019-0834-0","volume":"18","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Node K. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials. Cardiovasc Diabetol. 2019;18:19.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01324-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01324-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01324-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T23:10:05Z","timestamp":1691363405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01324-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01324-9","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KS declares no conflicts of interest associated with this manuscript. AT has received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline, Takeda, Bristol Myers Squibb, and Novo Nordisk. KN has received honoraria from MSD, Astellas, AstraZeneca, Novartis, Ono, Daiichi Sankyo, Mitsubishi Tanabe, Eli Lilly, Boehringer Ingelheim, and Takeda; research grants from Asahi Kasei, Astellas, Mitsubishi Tanabe, Teijin, Terumo, Boehringer Ingelheim, Eli Lilly and Company, Mochida, and Fuji; and scholarships from Daiichi Sankyo Healthcare, Teijin, Medtronic, and Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}